United Therapeutics Corporation Aktie News

The biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments while offering investors the possibility of significant returns. However, investing in these companies requires a nuanced understanding of their pipelines, regulatory landscapes and market dynamics.

The top five biotech stocks today have several commonalities. Among them are strong ratings.

United Therapeutics delivered substantial revenue and EPS beats in Q1. Tyvaso products sales grew by 56%, highlighting the successful commercial launch of Tyvaso DPI.

United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Leigh Peterson - Executive Vice President-Product Develo...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023. “The first quarter of 20...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Please replace the photo for release dated April 24, 2024 with the accompanying corrected photo. The release reads: UNITED THERAPEUTICS ANNOUNCES WORLD'S FIRST SUCCESSFUL XENOTHYMOKIDNEY TRANSPLANT The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world's first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024. This transplant represents several historic firsts for transplantation: - The first-ever transplant of a xe...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public w...